血浆血管性血友病因子水平与未来静脉血栓栓塞症风险
Several case-control studies have reported elevated plasma von Willebrand factor (VWF) levels in patients with venous thromboembolism (VTE) compared with controls.…
要点
- 血浆VWF水平与VTE风险呈剂量依赖关系,最高四分位OR 1.45(95%CI 1.03-2.03)。
- 无诱因VTE风险最强(OR 2.74),无诱因DVT尤为显著(OR 6.73)。
- VWF可能是未来VTE风险的候选生物标志物,尤其针对无诱因事件。
核心结论
- 血浆VWF水平与未来初发VTE风险呈剂量依赖关系,无诱因事件尤为显著。
- VWF可能是预测未来VTE风险的候选生物标志物。
研究设计与样本
- 基于Tromsø研究队列(1994-2007)的人群基础巢式病例对照研究。
- 纳入414例VTE病例和843例年龄性别匹配对照。
- 血样于队列基线(1994-1995)采集。
主要发现
- 最高四分位VWF者VTE的OR为1.45(95%CI 1.03-2.03)。
- 无诱因VTE的OR为2.74(95%CI 1.66-4.54),无诱因DVT的OR为6.73(95%CI 3.07-14.76)。
- 进一步校正BMI、CRP、高血压、雌激素使用和吸烟后风险估计变化不大。
临床怎么用
- 解读血浆VWF水平时需考虑其与未来VTE风险的关联,尤其无诱因事件。
- VWF可作为研究或风险评估场景中的潜在生物标志物,尚需进一步验证。
局限性
- 研究为病例对照设计,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several case-control studies have reported elevated plasma von Willebrand factor (VWF) levels in patients with venous thromboembolism (VTE) compared with controls. However, because few studies have investigated the association in a prospective design, it is unclear whether elevated plasma VWF is a risk factor or a consequence of the VTE event. Therefore, we aimed to investigate the prospective association between plasma VWF levels and risk of VTE, as well as to perform subgroup analyses of deep vein thrombosis (DVT) and pulmonary embolism. We established a population-based nested case-control study of 414 VTE cases and 843 age- and sex-matched controls based on the Tromsø study cohort (1994-2007). Blood samples were collected at cohort baseline (1994-1995). Odds ratios (ORs) with 95% confidence intervals (CIs) for VTE were estimated across quartiles of VWF levels. We found that the risk of VTE increased linearly across quartiles of VWF levels (P for trend = .023). Participants with VWF in the highest quartile had an OR of 1.45 (95% CI, 1.03-2.03) for VTE compared with those in the lowest quartile. The association was strongest for unprovoked VTE (OR, 2.74; 95% CI, 1.66-4.54) and unprovoked DVT in particular (OR, 6.73; 95% CI, 3.07-14.76). Further adjustment for body mass index, C-reactive protein, hypertension, estrogen use, and smoking had a modest effect on the risk estimates. To conclude, we found a dose-dependent relationship between plasma VWF levels and future risk of incident VTE, and unprovoked events in particular. Our findings suggest that VWF may represent a promising biomarker for future risk of incident VTE.
引用
- Edvardsen MS, Hindberg K, Hansen ES, et al. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv. 2021. PMID: 33570640. doi:10.1182/bloodadvances.2020003135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。